CompletedPhase 2NCT03173950

Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers

Studying Medulloblastoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
National Cancer Institute (NCI)
Principal Investigator
Byram H Ozer, M.D.
National Cancer Institute (NCI)
Intervention
Nivolumab(drug)
Enrollment
133 enrolled
Eligibility
18-99 years · All sexes
Timeline
20172025

Study locations (3)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03173950 on ClinicalTrials.gov

Other trials for Medulloblastoma

Additional recruiting or active studies for the same condition.

See all trials for Medulloblastoma

← Back to all trials